This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2007.05.018v1 50/9/831    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Olivotto, I. Articles by Maron, B. J. Search for Related Content PubMed PubMed Citation Articles by Olivotto, I. Articles by Maron, B. J. Related Collections Related Article

VIEWPOINT

Surgical Myectomy Versus Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy

Will There Ever Be a Randomized Trial?

Iacopo Olivotto, MD^_*,_*, Steve R. Ommen, MD, Martin S. Maron, MD, Franco Cecchi, MD^_* and Barry J. Maron, MD

^_* Referral Center for Myocardial Diseases, Department of Cardiology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy
Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota
Cardiology Division, Tufts–New England Medical Center, Boston, Massachusetts.

Manuscript received November 21, 2006; revised manuscript received May 10, 2007, accepted May 15, 2007.

^_* Reprint requests and correspondence: Dr. Iacopo Olivotto, Cardiologia San Luca, Azienda Ospedaliera Universitaria Careggi, Viale Pieraccini 17, 50132, Florence, Italy. (Email: olivottoi{at}ao-careggi.toscana.it).

Dynamic left ventricular outflow tract obstruction is an important pathophysiologic feature of hypertrophic cardiomyopathy (HCM) and a predictor of clinical deterioration and cardiovascular mortality. Patients with marked obstruction and severe limiting symptoms refractory to maximum medical management are considered candidates for invasive septal reduction therapy, which includes surgical myectomy and alcohol septal ablation (ASA). Availability of both surgical myectomy and ASA has polarized the cardiovascular community concerning the most appropriate implementation of these two interventions. The ensuing controversy of whether myectomy and ASA are truly equivalent options has resulted in calls for a prospective randomized trial. However, upon analysis, such a myectomy versus ASA trial, adequately powered to compare the key issue of long-term outcome, poses a myriad of practical problems that seem virtually insurmountable. Therefore, it is appropriate to revisit this evolving debate at this time, identify the unique obstacles to a randomized study design, and achieve some clarity concerning the most realistic clinical strategies for symptomatic patients with HCM and outflow obstruction.

Abbreviations and Acronyms   ASA = alcohol septal ablation   CABG = coronary artery bypass graft surgery   HCM = hypertrophic cardiomyopathy   LV = left ventricular   PTCA = percutaneous transluminal coronary angioplasty   SAM = systolic anterior motion

Related Article

Inside This Issue of JACC
J. Am. Coll. Cardiol. 2007 50: A31-A32. [Full Text] [PDF]

This article has been cited by other articles:

				B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, H. Rakowski, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons J. Am. Coll. Cardiol., December 13, 2011; 58(25): 2703 - 2738. [Full Text] [PDF]

				B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, H. Rakowski, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons J. Am. Coll. Cardiol., December 13, 2011; 58(25): e212 - e260. [Full Text] [PDF]

				Writing Committee Members, B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation, December 13, 2011; 124(24): e783 - e831. [Full Text] [PDF]

				Writing Committee Members, B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation, December 13, 2011; 124(24): 2761 - 2796. [Full Text] [PDF]

				Writing Committee Members:*, B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J. Thorac. Cardiovasc. Surg., December 1, 2011; 142(6): 1303 - 1338. [Full Text] [PDF]

				Writing Committee Members:*, B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J. Thorac. Cardiovasc. Surg., December 1, 2011; 142(6): e153 - e203. [Full Text] [PDF]

				W. Ball, J. Ivanov, H. Rakowski, E. D. Wigle, M. Linghorne, A. Ralph-Edwards, W. G. Williams, L. Schwartz, A. Guttman, and A. Woo Long-Term Survival in Patients With Resting Obstructive Hypertrophic Cardiomyopathy: Comparison of Conservative Versus Invasive Treatment J. Am. Coll. Cardiol., November 22, 2011; 58(22): 2313 - 2321. [Abstract] [Full Text] [PDF]

				S. F. Nagueh, B. M. Groves, L. Schwartz, K. M. Smith, A. Wang, R. G. Bach, C. Nielsen, F. Leya, J. M. Buergler, S. K. Rowe, et al. Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy: A Multicenter North American Registry J. Am. Coll. Cardiol., November 22, 2011; 58(22): 2322 - 2328. [Abstract] [Full Text] [PDF]

				B. J. Maron, M. Yacoub, and J. A. Dearani Benefits of surgery in obstructive hypertrophic cardiomyopathy: bring septal myectomy back for European patients Eur. Heart J., May 1, 2011; 32(9): 1055 - 1058. [Abstract] [Full Text] [PDF]

				M. A. Fifer and U. Sigwart Hypertrophic obstructive cardiomyopathy: alcohol septal ablation Eur. Heart J., May 1, 2011; 32(9): 1059 - 1064. [Abstract] [Full Text] [PDF]

				F. J. ten Cate, O. I. I. Soliman, M. Michels, D. A. M. J. Theuns, P. L. de Jong, M. L. Geleijnse, and P. W. Serruys Long-Term Outcome of Alcohol Septal Ablation in Patients With Obstructive Hypertrophic Cardiomyopathy: A Word of Caution Circ Heart Fail, May 1, 2010; 3(3): 362 - 369. [Abstract] [Full Text] [PDF]

				R. A. Leonardi, E. P. Kransdorf, D. L. Simel, and A. Wang Meta-Analyses of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy: Comparative Rates of Overall Mortality and Sudden Cardiac Death After Treatment Circ Cardiovasc Interv, April 1, 2010; 3(2): 97 - 104. [Abstract] [Full Text] [PDF]

				S. Agarwal, E. M. Tuzcu, M. Y. Desai, N. Smedira, H. M. Lever, B. W. Lytle, and S. R. Kapadia Updated Meta-Analysis of Septal Alcohol Ablation Versus Myectomy for Hypertrophic Cardiomyopathy J. Am. Coll. Cardiol., February 23, 2010; 55(8): 823 - 834. [Abstract] [Full Text] [PDF]

				C. Knight and S. A. Mohiddin Chapter 41 Alcohol septal ablation for obstructive hypertrophic cardiomyopathy Oxford Textbook of Interventional Cardiology, January 1, 2010; 1(1): med-9780199569083-chapter - med-9780199569083-chapter. [Abstract] [Full Text]

				P. Sorajja, R. A. Nishimura, B. J. Gersh, J. A. Dearani, D. O. Hodge, H. J. Wiste, and S. R. Ommen Outcome of Mildly Symptomatic or Asymptomatic Obstructive Hypertrophic Cardiomyopathy: A Long-Term Follow-Up Study J. Am. Coll. Cardiol., July 14, 2009; 54(3): 234 - 241. [Abstract] [Full Text] [PDF]

				S R Ommen, P M Shah, and A J Tajik Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: past, present and future Heart, October 1, 2008; 94(10): 1276 - 1281. [Full Text] [PDF]